id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2023-0009,FDA,FDA-2020-E-2023,NOTICE OF FINAL DETERMINATION,Other,Letter(s),2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T15:17:23Z,,0,0,0900006486621357
FDA-2020-E-2023-0008,FDA,FDA-2020-E-2023,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-08-01T04:00:00Z,2022,8,2022-08-01T04:00:00Z,,2022-08-01T15:11:49Z,,0,0,0900006485200bca
FDA-2020-E-2023-0006,FDA,FDA-2020-E-2023,Patent Term Extension Approval letter from FDA CDER,Other,Approval,2021-11-05T04:00:00Z,2021,11,2021-11-05T04:00:00Z,,2021-11-05T15:51:50Z,,0,0,0900006484e24e27
FDA-2020-E-2023-0005,FDA,FDA-2020-E-2023,Determination of Regulatory Review Period for Purposes of Patent Extension; RECARBRIO,Notice,Determinations,2021-11-04T04:00:00Z,2021,11,2021-11-04T04:00:00Z,2022-01-04T04:59:59Z,2021-11-05T01:00:49Z,2021-24068,0,0,0900006484e17dd7
FDA-2020-E-2023-0004,FDA,FDA-2020-E-2023,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T17:08:32Z,,0,0,0900006484c0f0d1
FDA-2020-E-2023-0003,FDA,FDA-2020-E-2023,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2021-01-04T05:00:00Z,2021,1,2021-01-04T05:00:00Z,,2021-01-04T17:02:11Z,,0,0,09000064849dbf48
FDA-2020-E-2023-0001,FDA,FDA-2020-E-2023,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2020-09-29T04:00:00Z,2020,9,2020-09-29T04:00:00Z,,2020-09-29T19:04:57Z,,0,0,090000648489b530
FDA-2020-E-2023-0002,FDA,FDA-2020-E-2023,Patent Extension Application from Merck Sharp & Dohme Corp.,Other,Application,2020-09-29T04:00:00Z,2020,9,2020-09-29T04:00:00Z,,2020-09-29T19:05:09Z,,0,0,090000648489b531